| Literature DB >> 23293609 |
Jennifer Malsert1, Nathalie Guyader, Alan Chauvin, Mircea Polosan, David Szekely, Thierry Bougerol, Christian Marendaz.
Abstract
BACKGROUND: The understanding of physiopathology and cognitive impairments in mood disorders requires finding objective markers. Mood disorders have often been linked to hypometabolism in the prefrontal dorsolateral cortex, and to GABAergic and glutamatergic neurotransmission dysfunction. The present study aimed to discover whether saccadic tasks (involving DPLFC activity), and cortical excitability (involving GABA/Glutamate neurotransmission) could provide neuropsychophysical markers for mood disorders, and/or of its phases, in patients with rapid cycling bipolar disorders (rcBD).Entities:
Keywords: GABA/glutamate; TMS; cortical excitability; inhibition/facilitation; paired-pulse; saccade
Year: 2013 PMID: 23293609 PMCID: PMC3537079 DOI: 10.3389/fpsyt.2012.00112
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Patient information.
| P1 | P2 | ||||||
|---|---|---|---|---|---|---|---|
| Thymic phase | Psychometric scores | Medication | Thymic phase | Psychometric scores | Medication | ||
| MADRS | YMRS | MADRS | YMRS | ||||
| Manic | 8 | 20 | LTG; CMZ | Depressive | 21 | 0 | Li; VPA; VFX |
| Euthymic | 12 | 4 | LTG | Euthymic | 8 | 6 | Li; VPA; VFX |
| Depressive | 28 | 0 | LTG; CMZ; S-Cit | Manic | 4 | 22 | Li; VPA; OLZ |
Abbreviations: MADRS, Montgomery and Asberg Depression Rating Scale; YMRS, Young Mania Rating Scale; LTG, lamotrigine; CMZ, cyamemazine; S-Cit, escitalopram; Li, Lithium; VPA, divalproex; VFX, venlafaxine; OLZ, olanzapine.
Figure 1Examples of trial sequences for the three saccadic conditions (red: AS, Blue: NS, and green: PS).
Figure 2Saccadic performance for each patient as a function of the two opposing illness phases (Depressive and Manic) and for controls (±CI). (A) Mean percentages of saccadic inhibition errors in antisaccades (AS) and nosaccades (NS). (B) Mean SRT (in milliseconds) in prosaccades (PS).
Saccadic inhibition error rates as a function of saccadic task (Antisaccade vs. Nosaccade), cue visual hemifield (Cue left vs. right), and illness phase (Depressive, Manic, Euthymic) for each patient (P1, P2) and for controls.
| Task | Antisaccade | Nosaccade | |||
|---|---|---|---|---|---|
| Cue location | Left (%) | Right (%) | Left (%) | Right (%) | |
| / | Controls | 14 | 16 | 1 | 2 |
| P1 | Depressive | 21 | 31 | 13 | 38 |
| Euthymic | 43 | 53 | 14 | 38 | |
| Manic | 40 | 71 | 67 | 100 | |
| P2 | Depressive | 93 | 93 | 0 | 17 |
| Euthymic | 100 | 93 | 14 | 0 | |
| Manic | 64 | 85 | 86 | 100 | |
Resting motor threshold (RMT), baseline MEP amplitude, and intracortical effects for short and long ISI for each hemisphere (LH/RH) in controls and patients.
| RMT (%) | Baseline (μV) | Short ISI (% change) | Long ISI (% change) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| LH | RH | LH | RH | LH | RH | LH | RH | ||
| Controls | 50 | 51 | 2118 | 1832 | −61.6 | −73.7 | 57.0 | 66.5 | |
| P1 | Depressive | 46 | 36 | 449 | 1441 | −59.2 | 55.4 | −22.6 | −6.4 |
| Euthymic | 43 | 32 | 1660 | 1434 | −22.8 | −65.6 | −11.6 | −71.1 | |
| Manic | 46 | 34 | 663 | 1352 | −28.0 | 0.6 | 60.3 | −1.8 | |
| P2 | Depressive | 48 | 44 | 1600 | 394 | −59.6 | −53.1 | 0.6 | 94.6 |
| Euthymic | 42 | 44 | 1520 | 1498 | −26.5 | −69.0 | 19.2 | 319 | |
| Manic | 42 | 48 | 328 | 630 | −56.1 | −55.5 | 69.9 | −38.6 | |
Figure 3Cortical excitability. (A) Baseline modifications (%) in controls and patients (depressive/manic) according to Inter Stimulus Intervals (ISI short/long). (B) Baseline modifications (%) in controls and patients (depressive/manic) according to stimulated hemisphere.